Concepedia

M. Lacevic

ML

7

Publications

1.2K

Citations

7

H-Index

2000

Active since

Affiliations

Moffitt Cancer Center(Current)

University of California, San Francisco

M. Lacevic is an author at Moffitt Cancer Center specializing in oncology, medicine, and breast cancer.

Top concepts

MedicineOncologyGynecologyPharmacologyBreast CancerAromataseEndocrinologyTumor BiologyCancer TherapyCancer Research

Publications per year

2000–2012

7

Publications

7

The uncertainty principle and industry-sponsored research

Benjamin Djulbegović, M. Lacevic, Alan Cantor et al. · The Lancet · 2000 · 488 citations

Uncertainty Management, High Uncertainty, Uncertainty Quantification +7

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

Pamela N. Münster, Kenneth T. Thurn, Scott Thomas et al. · British Journal of Cancer · 2011 · 386 citations · Full text

Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer

Pamela N. Münster, Amy P. Moore, Roohi Ismail‐Khan et al. · Journal of Clinical Oncology · 2012 · 238 citations · Full text

Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy

Roohi Ismail‐Khan, S. Minton, Catrin Cox et al. · Journal of Clinical Oncology · 2008 · 53 citations

Reproductive Sciences, Breast Oncology, Reproductive Health +23

Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy

Pamela N. Münster, M. Lacevic, Scott Thomas et al. · Journal of Clinical Oncology · 2009 · 16 citations

Breast Oncology, Histone Deacetylase Inhibitor, Estrogen Receptor +20

Rows per page

1–5 of 7